Cellebrite DI Ltd.CLBTNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank61
5Y CAGR-15.7%
Year-over-Year Change
Year-over-year research & development expense growth
5Y CAGR
-15.7%/yr
Long-term compound
Percentile
P61
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 6.19% |
| Q3 2025 | -1.70% |
| Q2 2025 | 4.89% |
| Q1 2025 | 6.55% |
| Q4 2024 | -1.26% |
| Q3 2024 | 9.42% |
| Q2 2024 | 2.14% |
| Q1 2024 | 6.65% |
| Q4 2023 | 6.36% |
| Q3 2023 | -2.86% |
| Q2 2023 | -0.37% |
| Q1 2023 | 7.08% |
| Q4 2022 | -8.79% |
| Q3 2022 | 9.96% |
| Q2 2022 | 0.51% |
| Q1 2022 | 3.95% |
| Q4 2021 | 14.65% |
| Q3 2021 | 6.75% |
| Q2 2021 | 3.32% |
| Q1 2021 | 0.83% |
| Q4 2020 | 14.51% |
| Q3 2020 | -5.86% |
| Q2 2020 | 5.36% |
| Q1 2020 | 0.00% |